Tyra Biosciences (NASDAQ:TYRA) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Tyra Biosciences (NASDAQ:TYRA) posted its quarterly earnings data on Thursday. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.05, Zacks reports.

Tyra Biosciences Stock Up 3.3 %

TYRA traded up $0.32 during trading on Friday, reaching $9.98. 66,265 shares of the company were exchanged, compared to its average volume of 231,451. The company has a market cap of $504.76 million, a price-to-earnings ratio of -6.17 and a beta of 1.09. Tyra Biosciences has a 12-month low of $9.49 and a 12-month high of $29.60. The company’s 50-day moving average is $12.59 and its two-hundred day moving average is $16.45.

Insider Buying and Selling at Tyra Biosciences

In other Tyra Biosciences news, Director Nina S. Kjellson sold 3,993 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total value of $65,325.48. Following the completion of the transaction, the director now directly owns 3,707,420 shares of the company’s stock, valued at $60,653,391.20. This trade represents a 0.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 21,998 shares of company stock valued at $344,818 in the last quarter. 15.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have issued reports on TYRA shares. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Tuesday, February 18th. UBS Group initiated coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.